TISIDB

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytoskeleton Nucleus Chromosome, centromere Chromosome, centromere, kinetochore Note=Associates with the microtubule network at the growing distal tip (the plus-end) of microtubules, probably through interaction with MTUS2/TIP150 and MAPRE1 (By similarity). Association with microtubule plus ends is also mediated by interaction with KIF18B. Centromeric localization requires the presence of BUB1 and SGO2.
Domain	PF00225 Kinesin motor domain
Function	In complex with KIF18B, constitutes the major microtubule plus-end depolymerizing activity in mitotic cells (PubMed:21820309). Regulates the turnover of microtubules at the kinetochore and functions in chromosome segregation during mitosis (PubMed:19060894). Plays a role in chromosome congression and is required for the lateral to end-on conversion of the chromosome-microtubule attachment (PubMed:23891108).

> Gene Ontology [ TOP ]
Biological Process	GO:0000070 mitotic sister chromatid segregation GO:0000226 microtubule cytoskeleton organization GO:0000819 sister chromatid segregation GO:0002478 antigen processing and presentation of exogenous peptide antigen GO:0002495 antigen processing and presentation of peptide antigen via MHC class II GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0006890 retrograde vesicle-mediated transport, Golgi to ER GO:0007018 microtubule-based movement GO:0007019 microtubule depolymerization GO:0007059 chromosome segregation GO:0007062 sister chromatid cohesion GO:0007067 mitotic nuclear division GO:0007080 mitotic metaphase plate congression GO:0007163 establishment or maintenance of cell polarity GO:0008608 attachment of spindle microtubules to kinetochore GO:0019882 antigen processing and presentation GO:0019884 antigen processing and presentation of exogenous antigen GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0030951 establishment or maintenance of microtubule cytoskeleton polarity GO:0030952 establishment or maintenance of cytoskeleton polarity GO:0031109 microtubule polymerization or depolymerization GO:0032984 macromolecular complex disassembly GO:0043241 protein complex disassembly GO:0043624 cellular protein complex disassembly GO:0048002 antigen processing and presentation of peptide antigen GO:0048193 Golgi vesicle transport GO:0050000 chromosome localization GO:0051261 protein depolymerization GO:0051303 establishment of chromosome localization GO:0051310 metaphase plate congression GO:0051315 attachment of mitotic spindle microtubules to kinetochore GO:0051640 organelle localization GO:0051656 establishment of organelle localization GO:0051983 regulation of chromosome segregation GO:0098813 nuclear chromosome segregation
Molecular Function	GO:0003774 motor activity GO:0003777 microtubule motor activity GO:0008017 microtubule binding GO:0015631 tubulin binding GO:0016887 ATPase activity GO:0019237 centromeric DNA binding GO:0051010 microtubule plus-end binding
Cellular Component	GO:0000775 chromosome, centromeric region GO:0000776 kinetochore GO:0000777 condensed chromosome kinetochore GO:0000779 condensed chromosome, centromeric region GO:0000793 condensed chromosome GO:0005871 kinesin complex GO:0005874 microtubule GO:0005875 microtubule associated complex GO:0005881 cytoplasmic microtubule GO:0035371 microtubule plus-end GO:0098687 chromosomal region GO:1990752 microtubule end

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-983231: Factors involved in megakaryocyte development and platelet production R-HSA-8856688: Golgi-to-ER retrograde transport R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic R-HSA-983189: Kinesins R-HSA-68886: M Phase R-HSA-2132295: MHC class II antigen presentation R-HSA-199991: Membrane Trafficking R-HSA-68882: Mitotic Anaphase R-HSA-2555396: Mitotic Metaphase and Anaphase R-HSA-68877: Mitotic Prometaphase R-HSA-195258: RHO GTPase Effectors R-HSA-5663220: RHO GTPases Activate Formins R-HSA-2500257: Resolution of Sister Chromatid Cohesion R-HSA-2467813: Separation of Sister Chromatids R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases R-HSA-5653656: Vesicle-mediated transport

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-6811434: COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-8856688: Golgi-to-ER retrograde transport
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-6811442: Intra-Golgi and retrograde Golgi-to-ER traffic
R-HSA-983189: Kinesins
R-HSA-68886: M Phase
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-68882: Mitotic Anaphase
R-HSA-2555396: Mitotic Metaphase and Anaphase
R-HSA-68877: Mitotic Prometaphase
R-HSA-195258: RHO GTPase Effectors
R-HSA-5663220: RHO GTPases Activate Formins
R-HSA-2500257: Resolution of Sister Chromatid Cohesion
R-HSA-2467813: Separation of Sister Chromatids
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KIF2C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between KIF2C and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
24987109	melanoma	Promote immunity (infiltration)	Both KIF2C and POLA2 have been found to play important roles in cell proliferation.

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KIF2C in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KIF2C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.712	0.0328
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.741	0.655
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.692	0.586
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.583	0.198
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.398	0.774
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.827	0.67
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.033	0.935
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.628	0.65
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.725	0.606
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.01	0.99
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.069	0.952
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.509	0.000261

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KIF2C in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	5.5	1.9	0.66
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	6.8	0.6	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	0	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIF2C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIF2C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIF2C. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIF2C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KIF2C expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KIF2C and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KIF2C
Name	kinesin family member 2C
Aliases	MCAK; CT139; KNSL6; kinesin-like 6 (mitotic centromere-associated kinesin); mitotic centromere-associated ki ......
Chromosomal Location	1p34.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KIF2C collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting KIF2C.

ID	Name	Drug Type	Targets	#Targets
DB04395	Phosphoaminophosphonic Acid-Adenylate Ester	Small Molecule	ACTA1, CCT3, CFTR, CSNK2A1, DAPK1, DTYMK, EPHA2, EPHB2, GALK1, GSK ......	26

Browse KIF2C